Sanjay Keswani

Sanjay Keswani

Company: Annexon Biosciences

Job title: Chief Medical Officer


Dr. Keswani joined Annexon Biosciences as Chief Medical Officer in June 2019.  He is an accomplished physician-scientist with broad R&D expertise in multiple therapeutic areas and is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom. Dr. Keswani has held senior executive positions in the pharmaceutical industry, including Roche, where he was Senior Vice President and Global Head of Neuroscience, Ophthalmology and Rare diseases Research and Early Development. During his tenure at Roche, his group successfully advanced five molecules to Phase 3 development. Prior to Roche, he was Vice President, Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology. He also held R&D leadership roles at Eli Lilly & Co. and Amgen, Inc. where he prosecuted the development of the now – approved CGRP antibodies for migraine prevention, Emgality and Aimovig. 


Leveraging Biomarkers to De-risk Clinical Development in Complement Mediated Diseases: Progress with Anti-C1q Inhibitor ANX005 12:30 pm

Download the Full Event Guide to find out more Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.